CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As previously mentioned in Zika communications distributed on September 21 and October 12, 2018; ord...
At CTS, we understand the impact converting to the Ortho viral marker platform has on your operation...
On April 15, 2019, the New CTS Laboratory Information System has been successfully implemented in Po...
On December 9, 2019, the new CTS Laboratory Information System successfully implemented in Phoe...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...